Table 2.

Antitubercular agents inhibiting mycolic acid biosynthesis.

No.	Target	Scaffold	SAR plan from hit	Most advanced analogue	In vivo efficacy	Ref.
1.1	InhA	Tetrahydro benzothieno pyrimidines			N/Da	(Vilcheze et al., 2011)
1.2		L-Prolinamides			Nob	(Encinas et al., 2014)
1.3		Thiadiazolyl methylthiazoles			Yesc	(Sink et al., 2015)
1.4		4-Hydroxy-2-pyridones			Yes	(Manjunatha et al., 2015; Ng et al., 2015)
1.5		Tetrahydropyranyl methylbenzamides			N/D	(Pajk et al., 2016)
2.1	KasA	Indazole sulfonamides			Yes	(Kumar et al., 2018; Cunningham et al., 2020)
3.1	Pks13	Benzofurans			Yes	(Ioerger et al., 2013; Aggarwal et al., 2017)

^aN/D, not determined; ^bNo, inactive in an acute TB infection mouse model; ^cYes, active in an acute TB infection mouse model.